VBL Therapeutics Discloses Data about VB-201 Novel Mechanism and Pre-Clinical Efficacy in Atherosclerosis VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis. The manuscript reports that VB-201 can broadly inhibit monocyte chemotaxis, with up to 90% efficacy in vitro.
July 8, 2013 - Business Wire via Yahoo! Finance